Allorion Therapeutics Inc, a clinical-stage biotechnology company that develops novel small molecule drugs for cancer and autoimmune diseases, today announced that two abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023, in Boston, Massachusetts.
Abstracts accepted for poster presentation:
Title: CDK2 inhibition demonstrates synthetic lethality in SCLC through apoptotic induction
Poster #: A022
Presenter: Nathan Schomer
Date and Time: Thursday, October 12; 12:30 p.m. – 4:00 p.m.
Title: The anti-tumor activity of CDK2 inhibition alone or in combination with other anti-cancer agents in human cancers
Poster #: B173
Presenter: Yaoyu Chen
Date and Time: Friday, October 13; 12:30 p.m. – 4:00 p.m.